Investor Relations

Press Releases

Date Title and Summary View
Apr 11, 2017

Confirms Plans to Re-submit New Drug Application for Twirla® by the end of the Second Quarter of 2017

Mar 16, 2017
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla ® , (ethinyl estradiol and levonorgestrel transdermal
Mar 08, 2017

Current Business Plan Expected to Extend Cash Position and Fund Operations into Q2 2018

Mar 01, 2017

Presentation Scheduled on Monday, March 13, 2017 at 4:30 PM Pacific Time

Feb 14, 2017

Presentation Scheduled on February 23, 2017 at 10:00 AM ET

Feb 02, 2017

Presentation Scheduled on Monday, February 13th, 2017 at 11:00 am ET

Jan 19, 2017

Presentation Scheduled on Tuesday, January 31, 2017 at 11:00 am ET

Jan 03, 2017
Resubmission of Twirla ® New Drug Application Expected to Address FDA's Complete Response Letter Company Plans to Resubmit NDA in First Half of 2017              Company to Host Conference Call on January 3, 2017 at 5:00 p.m. Eastern Time                PRINCETON, N.J., Jan.
Dec 22, 2016

Presentation Scheduled on Monday, January 9, 2017 at 9:00 AM Pacific Time

Dec 22, 2016

Presentation Scheduled on Thursday, January 12th, 2017 at 11:30 AM Pacific Time